ArticleJournal of clinical microbiology2009
Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting.
Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 124 citations in OpenAlex.
- Misdiagnosis of HIV infection during a South African community-based survey: implications for rapid HIV testing.Journal of the International AIDS Society · 2017Trial
- Use of a multifaceted approach to analyze HIV incidence in a cohort study of women in the United States: HIV Prevention Trials Network 064 Study.The Journal of infectious diseases · 2013Trial
- HIV surveillance in a large, community-based study: results from the pilot study of Project Accept (HIV Prevention Trials Network 043).BMC infectious diseases · 2011Trial
- The Origins and Genetic Diversity of HIV-1: Evolutionary Insights and Global Health Perspectives.International journal of molecular sciences · 2025Review
- When Acute Epstein-Barr Virus Mimics HIV: A Case of False-Positive p24 Antigen and Low-Level HIV Antibody Reactivity.Cureus · 2025Article
- HIV-1 virion lysis following centrifugation improves the sensitivity of the Fourth-Generation HIV Ag/Ab combo assay.BMC research notes · 2024Article
- Performance Evaluation of Microscanner Plus, an Automated Image-Based Cell Counter, for Counting CD4+ T Lymphocytes in HIV Patients.Diagnostics (Basel, Switzerland) · 2023Article
- Article
- Utility of the Signal-to-Cutoff Ratio and Antigen Index from Fourth- and Fifth-Generation HIV-1/HIV-2 Antigen/Antibody Assays for the Diagnosis of Acute HIV Infection: Applicability for Real-Time Use for Immediate Initiation of Antiretroviral Therapy.Journal of clinical microbiology · 2022Article
- Development of quantified HIV-1 antigen panel for evaluating HIV Ag/Ab combination tests using the RT-qPCR method.Practical laboratory medicine · 2022Article
- Engineering light-initiated afterglow lateral flow immunoassay for infectious disease diagnostics.Biosensors & bioelectronics · 2022Article
- A pilot study to assess the performance of a rapid ultrasound particle agglutination method for the detection of HIV antibodies.Journal of immunoassay & immunochemistry · 2022Article
- An Analysis of Predictive Sample-to-Cutoff Index for HIV Infection Confirmation Using Elecsys® HIV Combi PT Assay.International journal of clinical practice · 2022Article
- False reactive HIV-1 diagnostic test results in an individual from Kenya on multiple testing platforms-A case report.IDCases · 2021Article
- Evaluation of the Abbott ARCHITECT HIV Ag/Ab combo assay for determining recent HIV-1 infection.PloS one · 2021Article
- Cell phone based colorimetric analysis for point-of-care settings.The Analyst · 2019Article
- HIV infection in Xi'an, China: epidemic characterization, risk factors to false positives and potential utility of the sample-to-cutoff index to identify true positives using Architect HIV Ag/Ab combo.Antimicrobial resistance and infection control · 2019Article
- No Time to Delay! Fiebig Stages and Referral in Acute HIV infection: Seattle Primary Infection Program Experience.AIDS research and human retroviruses · 2018Observational
- Performance of the Alere Determine™ HIV-1/2 Ag/Ab Combo Rapid Test with algorithm-defined acute HIV-1 infection specimens.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2018Article
- Platinum Nanocatalyst Amplification: Redefining the Gold Standard for Lateral Flow Immunoassays with Ultrabroad Dynamic Range.ACS nano · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
An immunoassay (IA) that simultaneously detects both antibody to human immunodeficiency virus (HIV) and HIV p24 antigen (Architect HIV Ag/Ab Combo) was evaluated for its ability to detect HIV infection by using a panel of specimens collected from individuals recently infected with HIV type 1 (HIV-1). This IA was found to be capable of detecting the majority (89%) of infections, including 80% of those considered acute infections based on the presence of HIV RNA and the lack of detectable antibody to HIV. Substantial improvements in detection of recent infections by the Architect HIV Ag/Ab Combo relative to previous generations of IAs as well as the capacity to detect acute infections have important implications for HIV prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.